MIRA MIRA Pharma Total Business Assets

Official company branding of mirapharmaceuticals.com (MIRA)

Drug development at MIRA Pharmaceuticals (MIRA) relies on laboratory automation, where robots search for new formulas around the clock. The current market quotes for total assets visualized below stand at 4.54. The biotech firm focuses on neurology, attracting experts with significant stock options. Due to the early testing stages of its anxiety and pain treatments, the company currently lacks profit and market pricing power.

MIRA Pharma (MIRA) Aggregate Company Assets: for the period 02/21/2024 - 10/31/2026

Analytical breakdowns and data insights for company mirapharmaceuticals.com (MIRA)

- market value and analyst target forecast:
Stock Price MIRA Pharmaceuticals, Inc.|MIRA - Price Target Chart
- market capitalization data:
Market Capitalization MIRA Pharmaceuticals, Inc.|MIRA - Enterprise Value
- book capitalization information:
Book Value per Share MIRA Pharmaceuticals|MIRA - Company Book Value|Market Value to Book Value mirapharmaceuticals.com|MIRA - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio MIRA Pharmaceuticals|MIRA - Long-Term Debt to Equity|Current Liabilities to Capital MIRA Pharmaceuticals, Inc.|MIRA - Company Total Debt|Debt to Net Assets Ratio MIRA Pharmaceuticals, Inc.|MIRA - Company Long-Term Debts|Current Liabilities MIRA Pharmaceuticals|Quick Ratio mirapharmaceuticals.com
- earnings and market multiples details:
MIRA - Company Net Income
Summary company analysis:MIRA Pharma (MIRA)
Core merchandise of MIRA Pharmaceuticals

For MIRA Pharmaceuticals, the company's asset history demonstrates the total volume of resources required to develop bioethical plant-based analgesic research and implement energy-efficient ESG standards. This metric, reverse-calculated via return on assets (ROA), allows investors to track the dynamics of the asset base in real-time, where a stable range confirms financial stability and sharp deviations signal potential risks.

Direct competitors

indivior.com (INDV) - Company Total Assets|Aggregate Company Assets Collegium Pharmaceutical, Inc.|Total Business Assets CRON (Cronos Group Inc)|Company Total Assets CGC|Company Total Assets Canna Cabana (HITI)|Aggregate Company Assets Aurora Cannabis Inc. ACB|Aggregate Asset Value ACHV|Skye Bioscience - Company Total Assets|Anebulo Pharmaceuticals Inc (ANEB) - Cumulative Company Assets|intercure.co (INCR) - Aggregate Company Assets|Company Assets Nutriband (NTRB)|Cumulative Company Assets NSRX|IGC: Aggregate Asset Value|Company Total Assets FLGC|IMCC: Total Asset Value of Company|Company Total Assets ADIL (Adial Pharmaceuticals, Inc.)|Company Total Assets Artelo Biosciences Inc. ARTL|ENSC - Aggregate Company Assets|Aggregate Asset Value TTNP (Titan Pharmaceuticals)|Greenlane (GNLN) - Aggregate Company Assets|Cumulative Company Assets InMed Pharmaceuticals Inc|Aggregate Company Assets Akanda Corporation|Cumulative Company Assets Enveric Corp (ENVB)|Company Total Assets BGXX|Company Total Asset Base Hempacco Co Inc.